NCT03091439终止2 期
A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-positive Organisms
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Allergan
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Number of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population
研究概览
简要总结
This clinical study will be a multi-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of osteomyelitis (first episode) defined by:
- •Pain or point tenderness upon palpation or probing to bone
- •Plain radiograph or Magnetic resonance imaging (MRI) consistent with osteomyelitis (indistinctly marginated edema-like pattern of bone marrow hypointensity on unenhanced T1-weighted sequences, hyperintensity on fat-saturated T2-weighted and Short tau inversion recovery (STIR) sequences and/or abnormal enhancement on gadolinium-enhanced fat-saturated T2-weighted sequences, with or without visible periostitis or cortical bone destruction) OR Gram-positive cocci documented on a baseline Gram-stain from a bone specimen
- •Elevated C-reactive protein (CRP) (low sensitivity) above the upper limit of normal (ULN) (reference range for low sensitivity CRP is 3-10 mg/L)
- •Subjects must be willing and able, if discharged from the hospital, to return to the hospital or a designated clinic for scheduled visits, treatment, laboratory tests, and other outpatient procedures as required by the protocol.
排除标准
- •Treatment with an investigational drug within 30 days preceding the first dose of investigational product.
- •Receipt of > 24 hours of potentially effective IV antibacterial therapy for osteomyelitis within 96 hours of randomization, unless the pathogen isolated was documented to be Methicillin-resistant Staphylococcus aureus (MRSA) that was resistant to the administered antibiotic.
- •A prior episode of osteomyelitis, or a failed course of therapy for osteomyelitis.
- •Infection associated with a burn wound, with a sacral decubitus ulcer, or with multiple sites of osteomyelitis.
- •Septic arthritis that is non-contiguous to osteomyelitis, as diagnosed by isolation of a pathogen from synovial fluid culture.
- •Immunosuppression/immune deficiency
- •Evidence of Gram-negative bacteria by Gram stain in the absence of Gram-positive organisms.
- •Gram-negative bacteremia
- •Patients with concomitant endocarditis, necrotizing fasciitis, or prosthetic material at the site of infection at the time of study initiation.
- •Infection due to an organism known prior to study entry to not be susceptible to dalbavancin (dalbavancin mean inhibitory concentration [MIC] > 0.25 μg/mL) or vancomycin (vancomycin MIC > 2 μg/mL).
- •Concomitant systemic antibacterial therapy for Gram-positive infections (eg, rifampin, gentamicin).
- •Known or suspected hypersensitivity to glycopeptide antibiotics.
- •Patients with a rapidly fatal illness, who are not expected to survive for 3 months.
- •Pregnant or nursing females; positive urine (or serum) pregnancy test at Screening (pre-menopausal females only) or after admission (prior to dosing)
- •Sexually active females of childbearing potential who are unwilling or unable to use an acceptable method of contraception from at least the first dose of study drug until the last pregnancy test.
研究组 & 干预措施
Dalbavancin
Experimental
Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
干预措施: Dalbavancin (Drug)
Standard of Care
Active Comparator
Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
干预措施: Standard of Care (Drug)
结局指标
主要结局
Number of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population
时间窗: Day 42
Clinical response can be either cure, failure, or indeterminate. Cure was defined as recovery without need for additional antibiotic therapy. Failure was defined as the requirement of additional antibiotic therapy, new purulence, amputation due to progression of infection, requiring \> 6 weeks of treatment in the SOC arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency. The number of participants in each response category is reported.
次要结局
- Number of Participants With Clinical Improvement at Day 28 in the Modified Intent-to-Treat (mITT) Population(Baseline (Day 0) to Day 28)
- Number of Participants With Clinical Improvement at Day 28 in the CE Population(Baseline (Day 0) to Day 28)
- Number of Participants With Clinical Response at Day 42 in the mITT Population(Day 42)
- Number of Participants With Clinical Response at Day 180 in the mITT and CE Populations(Day 180)
- Number of Participants With Clinical Response at Day 365 in the mITT and CE Populations(Day 365)
- Number of Participants With Clinical Response by Pathogen at Day 180 in the CE Population(Day 180)
- Number of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population(Day 42)
- Number of Participants With Clinical Response by Pathogen at Day 42 in the CE Population(Day 42)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With OsteomyelitisOsteomyelitisNCT02685033Durata Therapeutics Inc., an affiliate of Allergan plc80
终止
2 期
Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar CholangiocarcinomaHilar CholangiocarcinomaNCT02955771Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.7
已完成
2 期
SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialMetastatic CancerRectal CancerMetastatic Colorectal CancerColon CancerColorectal CancerCancerNCT00418938Amgen266
已完成
2 期
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.Leukemia, Myeloid, AcuteNCT02450877Celgene7
已完成
2 期
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line TherapyNeoplasms, ColorectalColorectal CancerNCT00967616Daiichi Sankyo100